Search results
Results from the WOW.Com Content Network
10–20% mortality generally. 10% mortality with treatment. Meningococcal disease describes infections caused by the bacterium Neisseria meningitidis (also termed meningococcus). [1] It has a high mortality rate if untreated but is vaccine-preventable. [2] While best known as a cause of meningitis, it can also result in sepsis, which is an even ...
Neisseria meningitidis, often referred to as the meningococcus, is a Gram-negative bacterium that can cause meningitis and other forms of meningococcal disease such as meningococcemia, a life-threatening sepsis. The bacterium is referred to as a coccus because it is round, and more specifically a diplococcus because of its tendency to form pairs.
The first meningococcal conjugate vaccine (MCV-4), Menactra, was licensed in the US in 2005, by Sanofi Pasteur; Menveo was licensed in 2010, by Novartis. Both MCV-4 vaccines are approved by the Food and Drug Administration (FDA) for people 2 through 55 years of age. Menactra received FDA approval for use in children as young as 9 months in ...
7.7 million (2019) [9] Deaths. 236,000 (2019) [9] Meningitis is acute or chronic inflammation of the protective membranes covering the brain and spinal cord, collectively called the meninges. [10] The most common symptoms are fever, intense headache, vomiting and neck stiffness and occasionally photophobia. [1]
Penbraya is a pentavalent conjugate vaccine developed by Pfizer for the prevention of invasive meningococcal disease in people 10 through 25 years of age. [2] Invasive meningococcal disease, caused by the bacterium Neisseria meningitidis, can lead to serious conditions such as meningitis (inflammation of the brain and spinal cord lining) and septicemia (bloodstream infection). [3]
Purpura fulminans is an acute, often fatal, thrombotic disorder which manifests as blood spots, bruising and discolouration of the skin resulting from coagulation in small blood vessels within the skin and rapidly leads to skin necrosis and disseminated intravascular coagulation. [2][3]
Meningoencephalitis may be one of the severe complications of diseases originating from several Rickettsia species, such as Rickettsia rickettsii (agent of Rocky Mountain spotted fever (RMSF)), Rickettsia conorii, Rickettsia prowazekii (agent of epidemic louse-borne typhus), and Rickettsia africae. It can cause impairments to the cranial nerves ...
African meningitis belt. The African meningitis belt is a region in sub-Saharan Africa where the rate of incidence of meningitis is very high. It extends from Senegal to Ethiopia, and the primary cause of meningitis in the belt is Neisseria meningitidis. The belt was first proposed by Léon Lapeyssonnie of the World Health Organization (WHO) in ...